Health2Sync partners with Novo Nordisk to support better insulin use

Taiwanese chronic disease treatment company Health2Sync has partnered with Danish pharmaceutical company Novo Nordisk to help patients undergoing insulin therapy transfer dose logs wirelessly to a mobile health app.

The Health2Sync mobile app can now sync patient dose logs, including time and dose per injection, from the newly released NovoPen 6 and NovoPen Echo Plus enabled by near-field communication.

This integration allows users to browse insulin measurements and analytics, along with other health data, in the Health2Sync app, while clinicians can view their insulin data on the Patient Management Platform.

The partnership is also launching a patient support program, which will create tailored and age-based educational content for patients with type 1 diabetes (T1D). This content includes information about their illness, insulin use, attention needed during seasonal changes, and ways of coping with adverse health conditions, as well as experiences shared by other Type 1 patients.

WHY IT MATTER

A century since the discovery of insulin, a hormone that enables the human body to use glucose, Health2Sync noted that one in two patients with type 2 diabetes is untreated, while the number of patients requiring insulin treatment is still between the ages of two. 150 and 200 million is located worldwide. †

Through a new support program and by enabling the integration of smart insulin pens with the Health2Sync app, “patients receiving insulin therapy can achieve optimal glucose control through improved communication and education,” said Ed Deng, CEO and co-founder of Health2Sync .

Takatsugu Den, director of the Diabetes and Obesity Business at Novo Nordisk Pharma, said they expect age-based educational content, including manga and animation“children and adolescents with T1D will be able to more easily receive information about treatment and that starting insulin treatment will become simpler and easier to adapt”.

For now, the service is available to Japanese patients with plans to introduce it to “other markets in the region,” Deng shared.

THE BIGGER TREND

Health2Sync’s latest partnership with a multinational drug maker follows another partnership with French pharmaceutical company Sanofi, signed last December. Sanofi will help Health2Sync roll out its upcoming insulin management solution, which will be built with titration algorithms to facilitate effective coordination between healthcare providers and patients.

Meanwhile, in November of last year, Health2Sync released an updated version of its mobile app in Japan made to Integrate continuous glucose monitoring data from the Abbott FreeStyle LibreLink mobile app. With the latest app, they can view their CGM data, along with numbers about their diet, weight, blood pressure, and exercise data captured by Fitbit.